MedTrace Logo

Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin

NCT05650502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2022-12-28

No results posted yet for this study

Summary

This study aims to evaluate the effects of SMC (Seasonal malaria chemoprevention) with Sulfadoxine-Pyrimethamine (SP) and Amodiaquine (AQ) on the evolution of anti-malarial immunity of children and their susceptibility to malarial infection.

This is a cross-sectional study on children aged 6 to 59 months with/without SMC in two villages in northern Benin. Sociodemographic and clinical data as well as repeated blood samples will be collected from 440 children (before, during and after treatment). Samples will be analyzed using a Luminex assay to investigate antibody responses to MSP (merozoite surface protein) , Glurp (Glutamate-Rich Protein) and a panel of PfEMP1. qPCR (quantitative polymerase chain reaction) will be used to detect the prevalence of malaria at this period and parasites infecting children will be characterize during the follow up.

Conditions

  • Plasmodium Malariae Infection
  • SMC
  • Immune System Disease

Interventions

DRUG

saisonal malaria chimoprevention

Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection

Sponsors & Collaborators

  • Institut de Recherche pour le Developpement

    collaborator OTHER_GOV

  • University of Copenhagen

    collaborator OTHER

  • University of Ghana

    collaborator OTHER

  • Institut de Recherche Clinique du Bénin (IRCB)

    collaborator UNKNOWN

  • Hôpital Cochin

    collaborator OTHER

  • Université de Parakou

    lead OTHER

Principal Investigators

  • Nicaise TIUKUE NDAM, Professor · Institut régional de développement IRD (UMR261)

  • Adrian LUTY, Professor · Institut régional de développement IRD (UMR261)

Eligibility

Min Age
6 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2021-08-30
Completion
2022-05-30
FDA Drug
Yes

Countries

  • Benin

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05650502 on ClinicalTrials.gov